- Home
- CURI vs CRBP Comparison
CURI vs CRBP Comparison
Compare CURI & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURI
- CRBP
- Stock Information
- Founded
- CURI N/A
- CRBP 2009
- Country
- CURI United States
- CRBP United States
- Employees
- CURI N/A
- CRBP N/A
- Industry
- CURI Movies/Entertainment
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- CURI Consumer Discretionary
- CRBP Health Care
- Exchange
- CURI Nasdaq
- CRBP Nasdaq
- Market Cap
- CURI 257.8M
- CRBP 210.8M
- IPO Year
- CURI N/A
- CRBP N/A
- Fundamental
- Price
- CURI $4.58
- CRBP $11.60
- Analyst Decision
- CURI Strong Buy
- CRBP Strong Buy
- Analyst Count
- CURI 3
- CRBP 9
- Target Price
- CURI $6.00
- CRBP $48.38
- AVG Volume (30 Days)
- CURI 1.0M
- CRBP 550.6K
- Earning Date
- CURI 11-12-2025
- CRBP 11-12-2025
- Dividend Yield
- CURI 7.02%
- CRBP N/A
- EPS Growth
- CURI N/A
- CRBP N/A
- EPS
- CURI N/A
- CRBP N/A
- Revenue
- CURI $66,595,000.00
- CRBP N/A
- Revenue This Year
- CURI $36.83
- CRBP N/A
- Revenue Next Year
- CURI $9.44
- CRBP $220.00
- P/E Ratio
- CURI N/A
- CRBP N/A
- Revenue Growth
- CURI 28.62
- CRBP N/A
- 52 Week Low
- CURI $1.47
- CRBP $4.64
- 52 Week High
- CURI $7.15
- CRBP $20.56
- Technical
- Relative Strength Index (RSI)
- CURI 54.53
- CRBP 41.12
- Support Level
- CURI $4.21
- CRBP $10.88
- Resistance Level
- CURI $5.00
- CRBP $12.43
- Average True Range (ATR)
- CURI 0.37
- CRBP 0.75
- MACD
- CURI 0.08
- CRBP 0.06
- Stochastic Oscillator
- CURI 69.81
- CRBP 65.02
About CURI CuriosityStream Inc.
CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. Its mission is to provide premium real entertainment that informs, enchants, and inspires. Its product and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, Enterprise Subscriptions and Others. The majority of the revenue comes from the Direct to direct-to-consumer business.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.